Strong profitability surge, but PAT guidance path tightens in H2
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 7/10
Grade B
FY27 AUM target (₹2,500 Cr) on track at 70.6% by H1; PAT guidance path tight—may miss without H2 acceleration.
Optimistic
next 1–2 quarters
Optimistic
multi-year
Mufin delivered strong Q2 (PAT +170% YoY, revenue +62%), pivoted to profitable digital lending, and reduced borrowing costs to 11.17%. However, FY27 PAT guidance of ₹80–90 Cr now requires ₹51–61 Cr in H2 versus H1's ₹29.1 Cr—a 1.75–2.1x jump unlikely at current 7.5% QoQ growth rates. Execution risk and tightening guidance path warrant Hold over Buy.
₹86.7 Cr
Revenue · +62.1% YoY₹15.1 Cr
Reported PAT · +169.5% YoYExpanding
Margins · vs guidance: MixedDid the claims hold up?
AUM tracking ₹2,500 Cr FY27 target, now at ₹1,766 Cr
METH1 ₹1,766 Cr is 70.6% of ₹2,500 Cr target; on pace if H2 grows ~11%, slightly ahead for flat YoY H2
FY27 PAT target ₹80–90 Cr on track
OVERSTATEDH1 ₹29.1 Cr is 32–36% of target; requires 51–61 Cr in H2 (1.75–2.1x H1), vs Q2 7.5% QoQ growth
Cost of borrowing reduced to 11.17% from 13.80%
METBorrowing costs fell 265 bps; enabled by onboarding PSU/large banks alongside existing funders
NPA improved sharply, gross 1.91%→1.77%, net 1.63%→1.50%
METNPA improvement confirmed; ₹30 Cr total, ₹29 Cr from EV retail legacy (99%), ₹1 Cr from new products
Digital lending now 44% of AUM, two products (Mediclaim ₹687 Cr, Salary Saathi ₹91 Cr)
METMediclaim 38.9% of AUM, Salary Saathi 5.1%; combined ₹778 Cr. Market position: Mediclaim 50+ competitors but Mufin claims market share and 20–25% annual growth
Earnings quality
What changed since the last call
Pivoted climate financing to digital-first
UpgradeClimate focus now zero (prior: material); climate book ₹160–180 Cr shrinking. Digital lending now 44% of AUM (Mediclaim ₹687 Cr, Salary Saathi ₹91 Cr), vs ~20% in FY26.
Cost of borrowing fell 265 bps
UpgradeReduced from 13.80% to 11.17% via PSU bank onboarding. Enables margin expansion; debt-to-equity at 2.89x (up from 2.43x) but lenders comfortable within ~4x limit.
NPA quality improved; legacy EV tail shrinking
UpgradeGross NPA 1.91%→1.77%, Net NPA 1.63%→1.50%. Of ₹30 Cr NPA, ₹29 Cr is legacy EV (99%), ₹1 Cr from new products. EV book performing well post-pivot.
AD-II license approved (not yet disclosed)
NewRegulatory win: Mufin applied directly for AD-II (forex dealer), unusual route. Plans new lending products; competitors mostly unsecured. Demonstrates RBI confidence but no revenue impact yet.
No H2 PAT guidance restatement
NeutralFY27 PAT ₹80–90 Cr target maintained verbally, but no explicit H2 narrowing. FY28 called "golden period" (vague). Suggests some caution on H2 certainty.
The Q&A
Investors (Karan Gala, Sandeep Kapadia) pressed hard on climate financing pain, NPA composition, AUM capacity, tech security, competitive moat, and AI adoption. Management held up well; answered most directly. Some hedging: AUM ceiling ₹3–3.5 Cr by FY27–28 (timeline withheld), AI roadmap deferred. Overall tone: confident on model, cautious on specifics.
Climate financing pain — Karan Gala, investor
AnsweredClimate focus zero. ₹100–110 Cr vehicle loans + ₹60–70 Cr battery loans remain; ₹25 Cr pain left in books. Rest of book (cars, buses) expected no major slippage.
NPA composition — Karan Gala, investor
AnsweredEV book: 99% NPA is legacy (already provisioned). Total NPA ~₹30 Cr; ₹29 Cr from EV retail, ₹1 Cr from new products. Recovery possible on new-product NPA.
AUM capacity & capital need — Karan Gala, investor
PartialNo fresh capital needed until ₹3,000–3,500 Cr AUM. Ambitious on FY27–28 targets but won't share numbers. Profit growth + lower costs will add capital. Dilution unacceptable; capital not a constraint.
Technology & security — Sandeep Kapadia, investor
AnsweredHired senior security personnel (Harish Arora from Ambit, Amit Sharma from SBI Cards). Migrated servers to AWS. Deployed SentinelOne for external breach blocking. Quarterly VAPT audits. Compliant with RBI Middle Layer NBFC rules; onboarding top-tier third-party vendors.
Competitive edge & moat — Sandeep Kapadia, investor
AnsweredProducts (Mediclaim, Arthum) differ in moat. Mediclaim: became commodity after 50 players entered; edge is service + innovation. Arthum: only 4 PPI licence holders in India; took 6 months to build (others need 1–1.5 yrs). Moat is PPI licence + tech ERP player (5–6 nationwide) + NBFC combo (vault with combo lock).
AI adoption in lending — Sandeep Kapadia, investor
PartialCurrently using AI in DevOps (coding) and collections (multilingual reminder bots). Not using AI for underwriting; focus on secured lending where collections largely secured. Team exploring underwriting AI but not priority yet. Will track future initiatives.
R&D and infrastructure tracking — Sandeep Kapadia, investor
AnsweredAgreed. KPIs should track four pillars: secured vs unsecured, scaling each segment, tech enablement, profitability via cost-of-capital reduction. These metrics should frame R&D and infrastructure spend.
Guidance
FY27 target implicit ~₹340–360 Cr (derived from ₹2,500 Cr AUM)
MediumH1 revenue ₹163.6 Cr (₹76.9+₹86.7); needs H2 ~₹176–196 Cr (8–20% growth). Current trajectory sustainable if Q3–Q4 average mid-₹85–₹90s Cr.
FY27 PAT target ₹80–90 Cr (NPM target ~22–25% on ₹340–360 Cr revenue)
LowH1 PAT ₹29.1 Cr (₹14+₹15.1); needs H2 ₹51–61 Cr. Q2 grew 7.5% QoQ; H2 needs 1.75–2.1x pace. No H2 guidance narrowing given.
Infrastructure investment rising to support Middle Layer NBFC compliance
MediumTech hiring (security CISOs), AWS migration, SentinelOne deployment, quarterly VAPT audits. OpEx expected to rise modestly; economies of scale to offset by FY28.
Risks the call surfaced
Execution on PAT guidance
HighH1 PAT ₹29.1 Cr is 32–36% of ₹80–90 Cr FY27 target; Q2 growth was 7.5% QoQ, far below the 1.75–2.1x needed in H2. No H2 guidance narrowing suggests management may accept shortfall.
Climate financing tail
Low₹160–180 Cr climate book shrinking; ₹100–110 Cr vehicle loans + ₹60–70 Cr battery loans. ₹25 Cr pain remaining; legacy EV account for 99% of ₹30 Cr total NPA. Expected "no major slippage", but EV market downturn could surprise.
Competition in digital lending
MediumMediclaim financing market now has 50+ players (vs 1–2 at launch). Mufin claims market size (~20–25% annual growth) can support all players, but yields under pressure. Salary Saathi and Arthum also face competitive replication risk. Mufin's edge claimed as service + innovation, but financial products become commodities.
Cyber security & data risk
MediumDigital lending platform (5–10 minute onboarding) attracts hacker attention; Mufin scaling tech infrastructure. Recently hired senior security CISOs (Harish Arora from Ambit, Amit Sharma from SBI), migrated to AWS, deployed SentinelOne, quarterly VAPT audits. Early mitigations in place, but risk elevated as they scale.
Regulatory transition to Middle Layer NBFC
LowMufin recently moved to Middle Layer NBFC (RBI scale-based regulation). New rules impose infrastructure, audit, and vendor onboarding requirements. OpEx expected to rise modestly; economies of scale to offset by FY28.
Management
Score 7/10. Clear on financials and business model; transparent on challenges (climate losses, NPA, competition). Some caution on specifics (AUM ceiling stated but timeline withheld, AI roadmap deferred). Honest on past mistakes (Blue Smart ₹15–20 Cr loss, climate 3-year 'mistake'). Delivered Q2 results on track: PAT +169.5% YoY, revenue +62.1% YoY, AUM target 70.6% by H1, borrowing costs down 265 bps. FY27 PAT guidance at risk (H1 is 36% of target, needs acceleration). Overall execution solid on profitability, tight on growth guidance.
1 · Q3 FY27
Early test of H2 momentum needed to track ₹80–90 Cr PAT; Arthum scaling begins
2 · Q4 FY27
Full-year PAT result; validate ₹2,500 Cr AUM target hit; AD-II license buildout timeline
3 · FY28
Management promised "golden period"; new products (impact lending, Arthum workforce) expected to scale
Execution risk and tightening guidance path warrant Hold over Buy.
Informational and educational content only. Not investment advice.